{"id":24474,"date":"2023-05-17T18:26:35","date_gmt":"2023-05-17T18:26:35","guid":{"rendered":"https:\/\/msdconecta.co.cr\/es\/?page_id=24474"},"modified":"2023-06-02T07:47:49","modified_gmt":"2023-06-02T07:47:49","slug":"estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307","status":"publish","type":"page","link":"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/","title":{"rendered":"Estadios del melanoma de alto riesgo de recurrencia"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/melanoma-header.jpg\" alt=\"\" class=\"wp-image-69088\"\/><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-white-color has-css-opacity has-white-background-color has-background\"\/>\n\n\n\n<h2 class=\"has-dark-blue-color wp-block-heading mhh-mcn-v1-heading--center mhh-mcn-v1-heading mhh-mcn-v1-heading--9d4430fef1a692a4956670eece325b8e\"><strong>Estadios del melanoma de alto riesgo de recurrencia <\/strong><br><strong>despu\u00e9s de la resecci\u00f3n<sup>1-4,a,b<\/sup><\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/melanoma-grafico.jpg\" alt=\"Estadios del melanoma de alto riesgo de recurrencia \ndespu\u00e9s de la resecci\u00f3n\" class=\"wp-image-69085\"\/><\/figure>\n\n\n\n<p class=\"has-negative-1-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c6445c31b37d7b296b41647422c2c86d\"><sup>a <\/sup>Basado en los criterios de estadificaci\u00f3n cl\u00ednica del melanoma del AJCC 8<sup>a<\/sup> edici\u00f3n.<br><sup>b <\/sup>Este material incluye informaci\u00f3n sobre el melanoma en estadio IIB, estadio IIC y estadio III. El melanoma en estadio IV que es resecable tambi\u00e9n es de alto riesgo, pero no se analiza en este material.<\/p>\n\n\n\n<section class=\"wp-block-mconnect-theme-section has-light-grey-background-color has-background sub__entry__content wp-block-mconnect-theme-section--align-full has-red-border-color\">\n\t<div class=\"mhh-mcn-container\">\n\t\t\n\n<h2 class=\"wp-block-heading mhh-mcn-v1-heading--center mhh-mcn-v1-heading mhh-mcn-v1-heading--fc93c151745e50ac54f8611507a176ae\"><strong>Supervivencia espec\u00edfica del melanoma<sup>5,a<\/sup><\/strong><\/h2>\n\n\n\n<nav class=\"wp-block-mconnect-theme-grid \">\n\t<ul class=\"is-grid-layout has-columns has-two-columns has-center-vertical-alignment\" >\n\t\t\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<p class=\"has-positive-2-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--86f341e87e8743119662d25acdb59207\"><strong>Supervivencia espec\u00edfica del <\/strong><br><strong>melanoma estimada a 5 a\u00f1os<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/supervivencia-melanoma1.jpg\" alt=\"Supervivencia espec\u00edfica del melanoma estimada a 5 a\u00f1os\" class=\"wp-image-69114\"\/><\/figure>\n\n\t<\/div>\n<\/li>\n\n\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/supervivencia-melanoma2.jpg\" alt=\"\" class=\"wp-image-69120\" width=\"588\" height=\"286\"\/><\/figure>\n\n\n\n<p class=\"entry__content has-dark-blue-background-color has-white-color has-positive-2-font-size has-border has-black-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--420f52ee7257b92842a1b163ae1b21ea\">La supervivencia espec\u00edfica del melanoma estimada por Kaplan-Meier para el estadio IIIB fue del <strong>83%<\/strong> a los 5 a\u00f1os. Para el melanoma en estadio IIB y IIC, la supervivencia espec\u00edfica del melanoma estimada a los 5 a\u00f1os fue del <strong>87% y 82%<\/strong> respectivamente.<\/p>\n\n\t<\/div>\n<\/li>\n\n\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<p class=\"   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1471eb2c3107c5aacd41a3c5209b7fd2\"><\/p>\n\n\t<\/div>\n<\/li>\n\n\t<\/ul>\n<\/nav>\n\n\n\n<p class=\"has-negative-1-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c22d2a5a13539564a5353d5cf4c3d833\"><sup>a<\/sup>Basado en las estimaciones de Kaplan-Meier de la supervivencia espec\u00edfica del melanoma (MSS) seg\u00fan lo informado por el panel de expertos en melanoma del AJCC<br>utilizando los criterios de estadificaci\u00f3n patol\u00f3gica del melanoma del AJCC 8<sup>a<\/sup> edici\u00f3n.<\/p>\n\n    <\/div>\n<\/section>\n\n\n\n<h2 class=\"wp-block-heading mhh-mcn-v1-heading--center mhh-mcn-v1-heading mhh-mcn-v1-heading--f413a0956abc42bd6b712db1248069cd\"><strong>Tasas de recurrencia en melanoma de alto riesgo resecado<\/strong><sup>2,3,4,6,a<\/sup><\/h2>\n\n\n\n<p class=\"has-positive-1-font-size mhh-mcn-v1-paragraph--left  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--e4700144f4f8061ecc9a2b026ba729c7\">Las recurrencias son comunes en el melanoma en estadio IIB y IIC resecado.<sup>2<\/sup><br>En melanoma en estadio III resecado, la recurrencia es com\u00fan.<sup>6<\/sup><br>Las tasas de recurrencia en melanoma de alto riesgo resecado: La recurrencia es <strong>ALTA<\/strong> tanto en los <strong>estadios IIB<\/strong> y <strong>IIC<\/strong> as\u00ed como en los estadios <strong>IIIA, IIIB y IIIC<\/strong>.<sup>2,6<\/sup><\/p>\n\n\n\n<nav class=\"wp-block-mconnect-theme-grid \">\n\t<ul class=\"is-grid-layout has-columns has-two-columns has-center-vertical-alignment\" >\n\t\t\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/tasa-recurrencia1.jpg\" alt=\"Tasas de recurrencia en\nestadio IIB y estadio IIC\" class=\"wp-image-69136\"\/><\/figure>\n\n\t<\/div>\n<\/li>\n\n\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/tasa-recurrencia2.jpg\" alt=\"Tasas de recurrencia en\nestadio III3,6,\" class=\"wp-image-69137\"\/><\/figure>\n\n\t<\/div>\n<\/li>\n\n\t<\/ul>\n<\/nav>\n\n\n\n<p class=\"has-negative-1-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--6f8a07a154cc31b58c7f7b9a5b16004f\"><sup>a<\/sup>De acuerdo con los criterios de estadificaci\u00f3n patol\u00f3gica del melanoma del AJCC 7<sup>a<\/sup> edici\u00f3n.<br><sup>b <\/sup>Revisi\u00f3n retrospectiva de 738 pacientes adultos con melanoma en estadio II resecado, de los cuales 338 ten\u00edan melanoma en estadio IIB o IIC resecado. Los pacientes de este estudio fueron tratados durante de 1993 &#8211; 2013 en el Memorial Sloan Kettering Cancer Center en Nueva York, NY.<br><sup>c <\/sup>Revisi\u00f3n retrospectiva de 251 pacientes de 2011 a 2016 con melanoma en estadio III resecado seguido de observaci\u00f3n y espera. Los pacientes incluidos en este estudio proced\u00edan de Am\u00e9rica del Norte, Am\u00e9rica del Sur y Europa.<\/p>\n\n\n\n<section class=\"wp-block-mconnect-theme-section has-dark-blue-background-color has-background sub__entry__content wp-block-mconnect-theme-section--align-full has-red-border-color\">\n\t<div class=\"mhh-mcn-container\">\n\t\t\n\n<h2 class=\"wp-block-heading mhh-mcn-v1-heading--center mhh-mcn-v1-heading mhh-mcn-v1-heading--244cb2734a56c5a83a357cbdd711dc32\"><strong>El melanoma a menudo reapareci\u00f3 con met\u00e1stasis distante<sup>2,3,6,a<\/sup><\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/recurrencia.png?w=1024\" alt=\"Seg\u00fan el estadio, entre el 30% y el\n54% de los pacientes con melanoma\nde alto riesgo resecado que reapareci\u00f3\npresentaron met\u00e1stasis a distancia.2,3,6\" class=\"wp-image-69143\"\/><\/figure>\n\n\n\n<nav class=\"wp-block-mconnect-theme-grid \">\n\t<ul class=\"is-grid-layout has-columns has-two-columns has-center-vertical-alignment\" >\n\t\t\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<p class=\"has-positive-2-font-size mhh-mcn-v1-paragraph--center  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--9b5338d8041d7c1497244f1d1e27beb9\">Recurrencias distantes en <br>estadio IIB y estadio IIC<sup>2,b<\/sup><\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full\"><img decoding=\"async\" src=\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/recurrencia-distante1.png\" alt=\"Recurrencias distantes en \nestadio IIB y estadio II\" class=\"wp-image-69152\"\/><\/figure>\n\n\n\n<p class=\" mhh-mcn-v1-paragraph--left  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c55f3021f4ca434caf6a43d5fbb21224\">Porcentaje de pacientes con primera recurrencia de melanoma como met\u00e1stasis distante.<\/p>\n\n\t<\/div>\n<\/li>\n\n\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<p class=\"has-positive-2-font-size mhh-mcn-v1-paragraph--center  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b29660030b4463098d41ad873ff283b5\">Recurrencias distantes <br>en estadio III<sup>6,c<\/sup><\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/recurrencia-distante2.png\" alt=\"\" class=\"wp-image-69153\"\/><\/figure>\n\n\n\n<p class=\" mhh-mcn-v1-paragraph--left  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--36fb642b7cd0b7ea29b991ec0acbf971\">Porcentaje de pacientes con primera recurrencia de melanoma como met\u00e1stasis distante o irresecable.<\/p>\n\n\t<\/div>\n<\/li>\n\n\t<\/ul>\n<\/nav>\n\n\n\n<p class=\"has-negative-1-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--51edcb7d6810adae1d620cd8f44f547e\"><sup>a<\/sup> De acuerdo con los criterios de estadificaci\u00f3n patol\u00f3gica del melanoma del AJCC 7<sup>a<\/sup> edici\u00f3n.<br><sup>b <\/sup>Revisi\u00f3n retrospectiva de 738 pacientes adultos con melanoma en estadio II resecado, de los cuales 338 ten\u00edan melanoma en estadio IIB o IIC resecado. Los pacientes de este estudio fueron tratados durante de 1993 &#8211; 2013 en el Memorial Sloan Kettering Cancer Center en Nueva York, NY.<br><sup>c<\/sup> Revisi\u00f3n retrospectiva de 251 pacientes de 2011 a 2016 con melanoma en estadio III resecado seguido de observaci\u00f3n y espera. Los pacientes incluidos en este estudio proced\u00edan de Am\u00e9rica del Norte, Am\u00e9rica del Sur y Europa.<\/p>\n\n    <\/div>\n<\/section>\n\n\n\n<h2 class=\"wp-block-heading mhh-mcn-v1-heading--center mhh-mcn-v1-heading mhh-mcn-v1-heading--b17012444ef282f439f12b6fea131d42\"><strong>Mediana de tiempo hasta la recurrencia en melanoma de alto riesgo resecado<sup>2,4,6,a<\/sup><\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/tiempo-recurrencia.png?w=1024\" alt=\"El 50% de todas las recurrencias de\nmelanoma de alto riesgo resecado\nocurrieron en menos de 2 a\u00f1os.2,6\" class=\"wp-image-69156\"\/><\/figure>\n\n\n\n<nav class=\"wp-block-mconnect-theme-grid \">\n\t<ul class=\"is-grid-layout has-columns has-two-columns has-center-vertical-alignment\" >\n\t\t\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<p class=\"has-positive-2-font-size mhh-mcn-v1-paragraph--center  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--524f253615c18d34c697b96d37a9f410\"><strong>Estadio IIB y IIC<\/strong><br><strong>Mediana de tiempo hasta la recurrencia<sup>2,b<\/sup><\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/tiempo-recurrencia-1-2.png\" alt=\"\" class=\"wp-image-69166\"\/><\/figure>\n\n\t<\/div>\n<\/li>\n\n\n\n<li class=\"wp-block-mconnect-theme-grid-item grid-item has-red-border-color\">\n\t<div class=\"sub__entry__content\">\n\t\t\n\n<p class=\"has-positive-2-font-size mhh-mcn-v1-paragraph--center  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--3ee38cdd4f44708d24dadd8c9b934367\"><strong>Estadio III<br>Mediana de tiempo hasta la recurrencia<sup>6,c<\/sup><\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/tiempo-recurrencia-2.png\" alt=\"Estadio III\nMediana de tiempo hasta la recurrencia\" class=\"wp-image-69162\"\/><\/figure>\n\n\t<\/div>\n<\/li>\n\n\t<\/ul>\n<\/nav>\n\n\n\n<p class=\"has-negative-1-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d4810da26be7853b1d352090e3b89e35\"><sup>a<\/sup>De acuerdo con los criterios de estadificaci\u00f3n patol\u00f3gica del melanoma del AJCC 7<sup>a<\/sup> edici\u00f3n.<br><sup>b<\/sup>Revisi\u00f3n retrospectiva de 738 pacientes adultos con melanoma en estadio II resecado, de los cuales 338 ten\u00edan melanoma en estadio IIB o IIC resecado. Los pacientes de este estudio fueron tratados durante de 1993 &#8211; 2013 en el Memorial Sloan Kettering Cancer Center en Nueva York, NY.<br><sup>c<\/sup>Revisi\u00f3n retrospectiva de 251 pacientes de 2011 a 2016 con melanoma en estadio III resecado seguido de observaci\u00f3n y espera. Los pacientes incluidos en este estudio proced\u00edan de Am\u00e9rica del Norte, Am\u00e9rica del Sur y Europa.<\/p>\n\n\n\n<section class=\"wp-block-mconnect-theme-section has-dark-blue-background-color has-background sub__entry__content wp-block-mconnect-theme-section--align-full has-red-border-color\">\n\t<div class=\"mhh-mcn-container\">\n\t\t\n\n<p class=\"has-negative-1-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--477434c22669918484636cd058241f9b\"><strong>Referencias: <\/strong><br>1 . Yushak M, Mehnert J, Luke J, Poklepovic A. Approaches to high-risk resected stage II and III melanoma. Am Soc Clin Oncol Educ Book. 2019;39:e207-e211. doi:10.1200\/ EDBK_239283.<br>2. Lee AY, Droppelmann N, Panageas KS, y cols. Patterns and timings of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol. 2017; 24(4):939-946. doi:10.1245\/s10434-016-5642-0.<br>3. Mohr P, Kiecker F, Soriano V, y cols. Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. Melanoma Manag. 2019;6(4):MMT33.doi:10.2217\/mmt-2019-0015.<br>4. Gershenwald JE, Scolyer RA, Hess KR y cols. Melanoma of the skin. AJCC Cancer Staging Manual. 8th ed. American Joint Committee on Cancer; 2017:563-585.<br>5. Gershenwald JE, Scolyer RA, Hess KR, y cols. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer (AJCC) Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2017;67(6):472-492.<br>6. Mohr P, Kiecker F, Soriano V, y cols. Anexo suplementario a: Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. Melanoma Manag. 2019;6(4):MMT33. doi:10.2217\/mmt-2019-0015.<\/p>\n\n    <\/div>\n<\/section>\n\n\n\n\n\n<p class=\"   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1471eb2c3107c5aacd41a3c5209b7fd2\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Estadios del melanoma de alto riesgo de recurrencia despu\u00e9s de la resecci\u00f3n1-4,a,b a Basado en los criterios de estadificaci\u00f3n cl\u00ednica [&hellip;]<\/p>\n","protected":false},"author":61360,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"hide_header":false,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"icon":null,"job_code":"","primary_tag":0,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","mconnectIsArchiveTemplate":false,"mconnectArchiveFiltersDisabled":false,"mconnectArchiveLockAllPresetFilters":false,"mconnectArchiveHidePageSubmenu":false,"mconnectArchiveShowParentPageOnly":false,"mconnectArchiveDefaultOrder":"DESC","mconnectArchiveDefaultOrderBy":"date","mconnectArchivePostsPerPage":12,"mconnectArchivePostTypes":[],"mconnectArchiveAllowFilterBy":["category","tx-content-type","tx-product","tx-pathology","tx-active-ingredient","tx-therapeutic-area"],"mconnectArchiveTaxonomyOrder":[],"mconnectArchiveFilterSorting":["is_keyword"],"mconnectArchiveContentItemStyle":{"showExcerpt":true,"showImage":true,"showIcon":false,"showPrimaryTag":true,"showBorder":false,"showDates":false,"showCta":true,"isCard":false,"hasBackground":false,"showMetadata":true},"mconnectArchiveLayout":{"type":"list","hasFeatured":false},"mconnectDynamicTaxonomyEntities":[],"mconnectArchiveTerms_category":[],"mconnectArchiveAllowTerms_category":[],"mconnectArchiveTerms_tx-content-type":[],"mconnectArchiveAllowTerms_tx-content-type":[],"mconnectArchiveTerms_tx-product":[],"mconnectArchiveAllowTerms_tx-product":[],"mconnectArchiveTerms_tx-pathology":[],"mconnectArchiveAllowTerms_tx-pathology":[],"mconnectArchiveTerms_tx-active-ingredient":[],"mconnectArchiveAllowTerms_tx-active-ingredient":[],"mconnectArchiveTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_dynamic-taxonomy":[],"mconnectArchiveLegacyDefaultTermsApplied":false,"mconnectContentUpdatesPerPage":10,"mconnectContentUpdatesViewMoreUrl":"","mconnectContentUpdatesTerms_tx-content-type":[],"mconnectContentUpdatesTerms_tx-product":[],"mconnectContentUpdatesTerms_tx-pathology":[],"mconnectContentUpdatesTerms_tx-active-ingredient":[],"mconnectContentUpdatesTerms_tx-therapeutic-area":[],"sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[],"tags":[],"ga4_page_audience":[1187],"ga4_page_birn_id":[],"ga4_page_branding":[],"ga4_page_businessunit":[],"ga4_page_campaign":[],"ga4_page_content_purpose":[400],"ga4_page_customer_journey_stage":[447],"ga4_page_customer_specialty":[484],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[],"ga4_page_product":[885],"ga4_page_region":[921],"ga4_page_therapeuticarea":[],"tx-therapeutic-area":[],"tx-product":[],"tx-pathology":[],"tx-content-type":[],"tx-active-ingredient":[],"mhh-area-of-interest":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-24474","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Estadios del melanoma de alto riesgo de recurrencia - MConnect Cenca Spanish<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estadios del melanoma de alto riesgo de recurrencia - MConnect Cenca Spanish\" \/>\n<meta property=\"og:description\" content=\"Estadios del melanoma de alto riesgo de recurrencia despu\u00e9s de la resecci\u00f3n1-4,a,b a Basado en los criterios de estadificaci\u00f3n cl\u00ednica [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/\" \/>\n<meta property=\"og:site_name\" content=\"MConnect Cenca Spanish\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-02T07:47:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/melanoma-header.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/\",\"url\":\"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/\",\"name\":\"Estadios del melanoma de alto riesgo de recurrencia - MConnect Cenca Spanish\",\"isPartOf\":{\"@id\":\"https:\/\/msdconecta.co.cr\/es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/melanoma-header.jpg\",\"datePublished\":\"2023-05-17T18:26:35+00:00\",\"dateModified\":\"2023-06-02T07:47:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/#breadcrumb\"},\"inLanguage\":\"es-CO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-CO\",\"@id\":\"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/#primaryimage\",\"url\":\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/melanoma-header.jpg\",\"contentUrl\":\"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/melanoma-header.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/msdconecta.co.cr\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estadios del melanoma de alto riesgo de recurrencia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/msdconecta.co.cr\/es\/#website\",\"url\":\"https:\/\/msdconecta.co.cr\/es\/\",\"name\":\"MConnect Cenca Spanish\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/msdconecta.co.cr\/es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/msdconecta.co.cr\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-CO\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/msdconecta.co.cr\/es\/#organization\",\"name\":\"MConnect Cenca Spanish\",\"url\":\"https:\/\/msdconecta.co.cr\/es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-CO\",\"@id\":\"https:\/\/msdconecta.co.cr\/es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/msdconecta.co.cr\/es\/wp-content\/uploads\/sites\/77\/2022\/07\/logo_tcm2359-1256911.png\",\"contentUrl\":\"https:\/\/msdconecta.co.cr\/es\/wp-content\/uploads\/sites\/77\/2022\/07\/logo_tcm2359-1256911.png\",\"width\":152,\"height\":48,\"caption\":\"MConnect Cenca Spanish\"},\"image\":{\"@id\":\"https:\/\/msdconecta.co.cr\/es\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estadios del melanoma de alto riesgo de recurrencia - MConnect Cenca Spanish","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/","og_locale":"es_ES","og_type":"article","og_title":"Estadios del melanoma de alto riesgo de recurrencia - MConnect Cenca Spanish","og_description":"Estadios del melanoma de alto riesgo de recurrencia despu\u00e9s de la resecci\u00f3n1-4,a,b a Basado en los criterios de estadificaci\u00f3n cl\u00ednica [&hellip;]","og_url":"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/","og_site_name":"MConnect Cenca Spanish","article_modified_time":"2023-06-02T07:47:49+00:00","og_image":[{"url":"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/melanoma-header.jpg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"6 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/","url":"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/","name":"Estadios del melanoma de alto riesgo de recurrencia - MConnect Cenca Spanish","isPartOf":{"@id":"https:\/\/msdconecta.co.cr\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/#primaryimage"},"image":{"@id":"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/#primaryimage"},"thumbnailUrl":"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/melanoma-header.jpg","datePublished":"2023-05-17T18:26:35+00:00","dateModified":"2023-06-02T07:47:49+00:00","breadcrumb":{"@id":"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/#breadcrumb"},"inLanguage":"es-CO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/"]}]},{"@type":"ImageObject","inLanguage":"es-CO","@id":"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/#primaryimage","url":"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/melanoma-header.jpg","contentUrl":"https:\/\/conecta.msd.com.ar\/wp-content\/uploads\/sites\/11\/2022\/10\/melanoma-header.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/msdconecta.co.cr\/es\/estadios-del-melanoma-de-alto-riesgo-de-recurrencia-wp-0307\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/msdconecta.co.cr\/es\/"},{"@type":"ListItem","position":2,"name":"Estadios del melanoma de alto riesgo de recurrencia"}]},{"@type":"WebSite","@id":"https:\/\/msdconecta.co.cr\/es\/#website","url":"https:\/\/msdconecta.co.cr\/es\/","name":"MConnect Cenca Spanish","description":"","publisher":{"@id":"https:\/\/msdconecta.co.cr\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/msdconecta.co.cr\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-CO"},{"@type":"Organization","@id":"https:\/\/msdconecta.co.cr\/es\/#organization","name":"MConnect Cenca Spanish","url":"https:\/\/msdconecta.co.cr\/es\/","logo":{"@type":"ImageObject","inLanguage":"es-CO","@id":"https:\/\/msdconecta.co.cr\/es\/#\/schema\/logo\/image\/","url":"https:\/\/msdconecta.co.cr\/es\/wp-content\/uploads\/sites\/77\/2022\/07\/logo_tcm2359-1256911.png","contentUrl":"https:\/\/msdconecta.co.cr\/es\/wp-content\/uploads\/sites\/77\/2022\/07\/logo_tcm2359-1256911.png","width":152,"height":48,"caption":"MConnect Cenca Spanish"},"image":{"@id":"https:\/\/msdconecta.co.cr\/es\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/pages\/24474","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/users\/61360"}],"replies":[{"embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/comments?post=24474"}],"version-history":[{"count":1,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/pages\/24474\/revisions"}],"predecessor-version":[{"id":24475,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/pages\/24474\/revisions\/24475"}],"wp:attachment":[{"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/media?parent=24474"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/categories?post=24474"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tags?post=24474"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_audience?post=24474"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_birn_id?post=24474"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_branding?post=24474"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_businessunit?post=24474"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_campaign?post=24474"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=24474"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=24474"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=24474"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_experience?post=24474"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_indication?post=24474"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_material_intent?post=24474"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_product?post=24474"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_region?post=24474"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=24474"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-therapeutic-area?post=24474"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-product?post=24474"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-pathology?post=24474"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-content-type?post=24474"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/tx-active-ingredient?post=24474"},{"taxonomy":"mhh-area-of-interest","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/mhh-area-of-interest?post=24474"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/access?post=24474"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/user_status?post=24474"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/msdconecta.co.cr\/es\/wp-json\/wp\/v2\/user_role?post=24474"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}